Cyclo Therapeutics (CYTH) Revenue & Revenue Breakdown
Cyclo Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.08M
Latest Revenue (Q)
$123.10K
Cyclo Therapeutics Revenue by Period
Cyclo Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.08M | -21.76% |
| 2022-12-31 | $1.38M | -13.24% |
| 2021-12-31 | $1.59M | 75.54% |
| 2020-12-31 | $903.38K | -10.31% |
| 2019-12-31 | $1.01M | -0.42% |
| 2018-12-31 | $1.01M | -18.28% |
| 2017-12-31 | $1.24M | -17.64% |
| 2016-12-31 | $1.50M | 58.13% |
| 2015-12-31 | $950.46K | -39.36% |
| 2014-12-31 | $1.57M | -7.43% |
| 2013-12-31 | $1.69M | 62.05% |
| 2012-12-31 | $1.04M | 1.27% |
| 2011-12-31 | $1.03M | 28.60% |
| 2010-12-31 | $802.37K | 28.61% |
| 2009-12-31 | $623.87K | 26.05% |
| 2008-12-31 | $494.94K | -34.11% |
| 2007-12-31 | $751.18K | 38.51% |
| 2006-12-31 | $542.31K | 19.36% |
| 2005-12-31 | $454.36K | -2.22% |
| 2004-12-31 | $464.69K | 17.78% |
| 2003-12-31 | $394.53K | -24.47% |
| 2002-12-31 | $522.37K | 80.49% |
| 2001-12-31 | $289.43K | -24.74% |
| 2000-12-31 | $384.59K | - |
Cyclo Therapeutics generated $1.08M in revenue during NA 2023, up -21.76% compared to the previous quarter, and up 106.42% compared to the same period a year ago.
Cyclo Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $123.10K | -39.19% |
| 2024-03-31 | $202.45K | -34.99% |
| 2023-12-31 | $311.40K | -37.15% |
| 2023-09-30 | $495.48K | 323.06% |
| 2023-06-30 | $117.12K | -23.16% |
| 2023-03-31 | $152.41K | -18.41% |
| 2022-12-31 | $186.80K | -58.69% |
| 2022-09-30 | $452.17K | -16.56% |
| 2022-06-30 | $541.89K | 178.03% |
| 2022-03-31 | $194.90K | -66.69% |
| 2021-12-31 | $585.12K | 44.86% |
| 2021-09-30 | $403.92K | 69.29% |
| 2021-06-30 | $238.59K | -33.38% |
| 2021-03-31 | $358.13K | 145.99% |
| 2020-12-31 | $145.59K | -34.56% |
| 2020-09-30 | $222.46K | 6.14% |
| 2020-06-30 | $209.59K | -35.65% |
| 2020-03-31 | $325.73K | 43.27% |
| 2019-12-31 | $227.36K | -20.48% |
| 2019-09-30 | $285.91K | 4.69% |
| 2019-06-30 | $273.10K | 23.67% |
| 2019-03-31 | $220.83K | -7.80% |
| 2018-12-31 | $239.51K | 6.70% |
| 2018-09-30 | $224.48K | -35.76% |
| 2018-06-30 | $349.42K | 76.41% |
| 2018-03-31 | $198.07K | 17.57% |
| 2017-12-31 | $168.47K | -30.14% |
| 2017-09-30 | $241.15K | -53.90% |
| 2017-06-30 | $523.09K | 71.47% |
| 2017-03-31 | $305.06K | -42.18% |
| 2016-12-31 | $527.64K | 89.67% |
| 2016-09-30 | $278.20K | -27.63% |
| 2016-06-30 | $384.39K | 22.93% |
| 2016-03-31 | $312.69K | 92.71% |
| 2015-12-31 | $162.26K | -30.85% |
| 2015-09-30 | $234.66K | -38.30% |
| 2015-06-30 | $380.34K | 119.60% |
| 2015-03-31 | $173.20K | -61.17% |
| 2014-12-31 | $446.03K | 15.10% |
| 2014-09-30 | $387.50K | 123.23% |
| 2014-06-30 | $173.58K | -69.02% |
| 2014-03-31 | $560.33K | 139.22% |
| 2013-12-31 | $234.23K | 40.02% |
| 2013-09-30 | $167.29K | -76.38% |
| 2013-06-30 | $708.32K | 21.39% |
| 2013-03-31 | $583.49K | 96.15% |
| 2012-12-31 | $297.47K | 89.02% |
| 2012-09-30 | $157.38K | 6.20% |
| 2012-06-30 | $148.19K | -66.47% |
| 2012-03-31 | $441.91K | 149.81% |
| 2011-12-31 | $176.90K | -23.50% |
| 2011-09-30 | $231.24K | -37.39% |
| 2011-06-30 | $369.35K | 45.20% |
| 2011-03-31 | $254.37K | -7.30% |
| 2010-12-31 | $274.39K | 39.61% |
| 2010-09-30 | $196.54K | 27.09% |
| 2010-06-30 | $154.64K | -8.78% |
| 2010-03-31 | $169.52K | 3.62% |
| 2009-12-31 | $163.60K | -24.03% |
| 2009-09-30 | $215.33K | 73.03% |
| 2009-06-30 | $124.45K | 3.28% |
| 2009-03-31 | $120.50K | -2.60% |
| 2008-12-31 | $123.71K | -12.95% |
| 2008-09-30 | $142.10K | -11.55% |
| 2008-06-30 | $160.66K | 134.64% |
| 2008-03-31 | $68.47K | -64.62% |
| 2007-12-31 | $193.54K | - |
Cyclo Therapeutics generated $123.10K in revenue during Q2 2024, up -39.19% compared to the previous quarter, and up 80.77% compared to the same period a year ago.
Cyclo Therapeutics Revenue Breakdown
Cyclo Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Mar 20 |
|---|---|
| Trappsol Cyclo | $30.10K |
| Product and Service, Other | $2.57K |
| Trappsol Fine Chemical | $78.11K |
| Trappsol HPB | $214.96K |
Latest
Cyclo Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 20: Trappsol HPB (65.99%), Trappsol Fine Chemical (23.98%), Trappsol Cyclo (9.24%), and Product and Service, Other (0.79%).
Cyclo Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 20 |
|---|---|
| Product and Service, Other | $2.57K |
| Trappsol Cyclo | $30.10K |
| Trappsol Fine Chemical | $78.11K |
| Trappsol HPB | $214.96K |
Latest
Cyclo Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 20: Trappsol HPB (65.99%), Trappsol Fine Chemical (23.98%), Trappsol Cyclo (9.24%), and Product and Service, Other (0.79%).
Cyclo Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.42M |
| AMRX | Amneal Pharmaceuticals | $2.39B | $702.47M |
| PAHC | Phibro Animal Health | $977.89M | $273.16M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $91.59M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| ASRT | Assertio | $152.07M | $29.20M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| AQST | Aquestive Therapeutics | $50.58M | $13.54M |
| TKNO | Alpha Teknova | $36.68M | $9.58M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| CYTH | Cyclo Therapeutics | $1.08M | $123.10K |
| ACRX | Talphera | $651.00K | $117.00K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |